We report the first case of haemophagocytic lymphohistiocytosis (HLH) in a neonate secondary to primary Dengue virus infection. This neonate presented in the third week of life with fever, shock and hepatosplenomegaly and was diagnosed to have Dengue infection by serology and HLH was confirmed on bone marrow.
ObjectiveTo reduce the incidence of metabolic bone disease (MBD) among very low birthweight (VLBW) infants admitted to neonatal intensive care unit from baseline of 35% by 50% over 2 years by implementing a quality improvement (QI) initiative.MethodsA multidisciplinary QI team used evidence-based interventions and the healthcare improvement model to reduce MBD rate in VLBW infants. The specific interventions included routine enteral supplementation of calcium and phosphorus using Human Milk Fortifier (HMF) to expressed breast milk by day 14 of life (Plan/Do/Study/Act (PDSA) cycle 1), parenteral and early enteral supplementation of calcium and phosphorus (PDSA cycles 2 and 3). We included VLBW infants admitted within the study period at birth and excluded babies with congenital malformations, skeletal disorders and those who died before 2 weeks of age. Compliance with adding HMF by day 14, compliance with adding calcium and phosphorus in total parenteral nutrition (TPN) from day 1 of life and compliance with starting HMF when the baby reached 100 mL/kg/day of feeds were used as process indicators. The incidence of MBD was used as an outcome indicator during the study. The incidence of MBD was tracked using the Statistical Process Control methodology.ResultsThe baseline MBD rate in 2015 was 35%. After the first PDSA cycle, 20% developed MBD (p=0.02). The same was sustained for a period of 1 year with the rate of 22%. After the second and third PDSA cycles, there was a drop in the MBD rate to 17%, and sustained for 3 months with 21%.ConclusionImplementation of QI initiatives decreased the MBD rate from 35% to <20%. Early parenteral calcium and phosphorus supplementation in TPN and optimising enteral supplementation with multicomponent fortifiers appear to have significant reduction in the incidence of MBD.
Background: The World Health Organization has declared coronavirus disease 2019 (COVID-19) a pandemic worldwide. Older people, individuals with comorbidities, and pregnant women are more susceptible to this virus, leading to adverse outcomes and mortality. Methods: Mothers with COVID-19 were divided into two groups of symptomatic and asymptomatic positive cases. Neonates were clinically evaluated and screened at 24 - 48 hours of age for SARS-CoV-2 by real-time polymerase chain reaction. Maternal and neonatal demographics, clinical characteristics, and follow-up at 14 days post-discharge were recorded. The adverse birth outcomes, preterm premature rupture of membrane (PPROM), cesarean section delivery (C-section), and duration of hospital stay were evaluated. Results: Out of 453 pregnant women, 59 (13.1%) and 394 (86.9%) were positive and negative for SARS-CoV-2, respectively. We subclassified 59 infected pregnant women were into two groups symptomatic (10.1%) and asymptomatic (89.8%). The PPROM (P = 0.001), gestational diabetes mellitus (P = 0.006), C-section (P = 0.002), and APGAR score (P = 0.029) had a significant association with SARS-CoV-2 presence in mothers and neonates. Conclusions: None of the neonates from infected pregnant women were infected with SARS-CoV-2, suggesting no negligible risk for mother-to-child transmission of the virus. However, the mother-newborn dyad needs to be followed up further to confirm our results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.